secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2025-02-11T23:59:59+00:00
Accession:  0001438533-25-000004
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere plans sNDA for FILSPARI in FSGS after FDA Type C meeting
----------------------------------------------------------------

- Completed Type C meeting with FDA; sNDA seeking traditional approval for FILSPARI in FSGS expected by end of Q1 2025.
- sNDA will rely on existing Phase 3 DUPLEX and Phase 2 DUET study data for FILSPARI.
- PARASOL workgroup findings show proteinuria reduction over 24 months strongly linked to lower kidney failure risk in FSGS.
- If approved, FILSPARI could become first and only approved therapy indicated for FSGS, a rare kidney disorder.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853325000004/0001438533-25-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853325000004/tvtx-20250211.htm
  HTML page:      https://secwatch.observer/filing/0001438533-25-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer